The complete line of BSD Hyperthermia products are availble thru Pyrexar Medical


PYREXAR® Medical:
The Leader in Hyperthermia Cancer Treatment Devices

PYREXAR Medical is the pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy / hyperthermia cancer treatment systems with established distribution and support networks in the US, Europe and Asia. PYREXAR HyperThermia treatments increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity in healthy tissues.

Certification logos

  • All
  • News
  • Product
  • Study
  • Video
  • Default
  • Title
  • Date
  • Random
  • Studies show that Hyperthermia, when added to Chemo or Radiation Increases positive outcomes
    Read More
    • Study
  • Deep Regional Hyperthermia producing excellent results when combined with Radiation or Chemotherapy.
    Read More
    • Product
  • Sarcoma Study Update

    Sarcoma Study Update

    Dr. Rolf Issels 5-year follow-up on Phase III EORTC hyperthermia plus chemotherapy study.
    • Study
    • Video
load more hold SHIFT key to load all load all

Who is Pyrexar Medical

Pyrexar Medical was formed to take on the fight against cancer. We purchased the Hyperthermia product line from BSD Medical in April 2015. Our plan is to support the existing BSD-500 and BSD-2000 customers, continue to make product improvements, support the growth of Thermal Oncology and spread the word about this amazing cancer therapy.


Leaders in Hyperthermia

33 years experience designing and building hyperthermia products for Oncology departments, research organizations and leading universities.

Clinical Results

Level 1 Clinical evidence that demonstrates how Hyperthermia makes a significant increase in cancer response rates.

Made in the USA

High quality products, made in the USA, with unrivaled customer service.


Where Have You Been? Trip Report : India

I just returned from a five day trip to India at the invitation of our distributor Kirloskar Technologies (KTPL). A special thanks to the planning and support of Mr. Ketan Desai, President of the Oncology Business at KTPL, for arranging the site visits and taking such good care of us. India is a very large market and can play an important role for growth of Pyrexar. To put the Indian market into perspective, the country represents just under 18% of the world population (1.34 billion population) packed into a land mass 1/3 the size of the US (323 million people). Treating the nation's cancer patients is a serious challenge.

Sasi Sekhar, KTPL Service Manager | Ketan Desai, President Oncology Business, KTPL | Dr. Geeta S Narayanan, Vydehi Institute | Mark Falkowski, CEO, Pyrexar Medical | Dr. Lokesh Viswanath | Dr. R. Vinaykumar

Mr. Sayan Bhattacharya | Dr. Jigna Bhattacharya, Assoc. Professor, Gujarat Cancer & Research Institute | Mark Falkowski, CEO, Pyrexar Medical | Ketan Desai, President Oncology Business, KTPL

Mark Falkowski, CEO, Pyrexar Medical | Dr. Nagraj Huilgol, Chief Radiation Oncologist, Nanavati Super Specialty Hospital | Ketan Desai, President Oncology Business, KTPL

Dr. Huilgol currently practicing at Nanavati. "Don't let the quaint exterior fool you, this is as modern a facility as any I have visited in the US" says Mark Falkowski


The journey took us down the western coast of India where we visited with several key hospitals targeted to introduce our radiative hyperthermia product line to the country. From Ahmedabad in the Northwestern state of Gujarat, to the coastal city of Mumbai in Maharashtra, to the southern city of Bangalore in Karnataka.  Information was well received, but they all asked the same question "Where have you been". That question is a little difficult to answer as our products are well established in European nations, in the US , China and growing rapidly on the Korean peninsula.

Where have you been? Why isn't Pyrexar in India?

Pyrexar has seen tremendous growth in the last three years. The regulatory requirements to enter each new country are rigorous and we have been working quickly to bring proven hyperthermia treatment to the world. As we start filling the void, lesser technologies are pushed aside and replaced. The plain truth to why we are not active in India is that we did not have solid distribution partners, until now. Kirloskar Technologies has the technical understanding, product depth and reach, and a service team that can handle our product line. With this partnership in place, it is possible to bring our systems to market in India.

One of the highlights of the trip was my meeting with Dr. Nagraj Huilgol. As you may know, Dr. Huilgol is a hyperthermia advocate and researcher with more than 100 publications in national and international journals. He was lead researcher in a phase III clinical study on head and neck cancer using capacitive hyperthermia. His CV includes Chief Editor of the Journal of Cancer Research and Therapeutics (JCRT) and a member of editorial boards of the Indian Journal of Cancer, Indian Journal of Head and Neck Cancer, International Journal of Hyperthermia and official journal of ASHO, ESHO and NAHO. Having this well known hyperthermia expert as a luminary will help usher hyperthermia into India.